Tumor targeted mesoporous silica nanoparticles functionalized with programmed death receptor ligand-1 antibody (anti-PD-L1) for combined chemo- and immunotherapy

Abstract

Traditional chemotherapy is associated with severe side-effects due to non-specific targeting of healthy tissue. An additional drawback of traditional chemotherapy is the development of multidrug resistance (MDR) phenotypes. Here, we overcome these issues by developing a targeted cancer drug delivery nanoplatform that combines immuno- and chemotherapy. We utilize mesoporous silica nanoparticles (MSNs) that are characterized by a high drug loading capacity (within the pores of the nanoparticles) and subsequent controlled drug release (in target cancer cells).